Thursday, September 19th, 2024

Problems in the medicine of Qmed and Lomus Pharmaceuticals

DDA directs to recall LEVOSAFE-500 and ZEFIX-100 from market


29 September 2021  

Time taken to read : 2 Minute


  • A
  • A
  • A

KATHMANDU: The Department of Drug Administration (DDA) has found two medicines of two Nepali pharmaceutical companies below the standard and has directed the concerned companies to recall the medicine from the market.

Issuing a statement on Wednesday, DDA has directed Qmed Formulation Pvt Ltd. Chhaling-5, Bhaktapur, Nepal and Lomus Prahmaceuticals Pvt. Ltd. Gothatar, Kathmandu, Nepal to recall the medicines identified as low quality medicines.

The department tested the products of both the pharmaceutical companies and found LEVOSAFE-500 (Levofloxacin 500 mg Tablets IP) of Qmed formulations and ZEFIX-100 (Cefixime 100 mg Dispersible Tablets IP) of Lomus Pharmaceuticals do not comply to IP 2018 with respect to dissolution test.

Both of these drugs are antibiotics.

After getting low quality medicine, the department has taken action as per the Drugs Act 1978.

The department has urged doctors not to prescribe those medicines.

Publish Date : 29 September 2021 14:46 PM

Today’s news in a nutshell

KATHMANDU: Khabarhub brings you a glimpse of major developments of

National Day Concert at Durbarmarg

KATHMANDU: On the occasion of Constitution Day, a ‘National Day

KMC gives Annapurna Neuro Hospital one week to improve hazardous waste management practices

KATHMANDU: The Kathmandu Metropolitan City (KMC) has issued a seven-day

Senior citizens now eligible for 50% healthcare discount at 64 hospitals across Nepal

KATHMANDU: In a move to address the healthcare needs of

Amendment of constitution as per public aspiration: Minister Khadka

KATHMANDU: Minister for Energy, Water Resources and Irrigation Deepak Khadka